for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Arca Biopharma Inc

ABIO.OQ

Latest Trade

5.74USD

Change

0.24(+4.36%)

Volume

3,076

Today's Range

5.49

 - 

5.74

52 Week Range

4.90

 - 

20.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

ARCA Biopharma Reports Q3 Loss Per Share Of $0.76

Nov 6 (Reuters) - ARCA Biopharma Inc <ABIO.O>::ARCA BIOPHARMA ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.76.CASH AND CASH EQUIVALENTS WERE $9.6 MILLION AS OF SEPTEMBER 30, 2019.

Arca Biopharma Posts Q2 Loss Per Share Of $1.14

Aug 1 (Reuters) - ARCA Biopharma Inc <ABIO.O>::ARCA BIOPHARMA ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $1.14.PRECISION-AF CLINICAL TRIAL INITIATION ANTICIPATED IN Q1 OF 2020.CASH AND CASH EQUIVALENTS WERE $9.97 MILLION AS OF JUNE 30, 2019, COMPARED TO $6.6 MILLION AS OF DECEMBER 31, 2018.ARCA BIOPHARMA - WILL NEED TO RAISE ADDITIONAL CAPITAL, AND/OR COMPLETE PARTNERSHIP OR OTHER POSSIBLE STRATEGIC TRANSACTION, TO FUND FUTURE OPERATIONS.ARCA - WILL NEED TO RAISE ADDITIONAL CAPITAL, COMPLETE PARTNERSHIP OR OTHER POSSIBLE STRATEGIC TRANSACTION, TO DEVELOP GENCARO OR ANY OTHER PRODUCT CANDIDATES.

Arca Biopharma Says Cash As Of March 31 To Be Sufficient To Fund Operations Through Q1 2020

June 28 (Reuters) - ARCA Biopharma Inc <ABIO.O>::ARCA BIOPHARMA SAYS ENTERED INTO AMENDMENT NO. 6 TO ITS CAPITAL ON DEMAND(TM)SALES AGREEMENT, DATED AS OF JANUARY 11, 2017 - SEC FILING.ARCA BIOPHARMA - AMENDMENT INCREASED MAXIMUM OFFERING VALUE OF SHARES OF CO'S STOCK WHICH CO MAY ISSUE, SELL UNDER AMENDED SALES AGREEMENT TO $17.5 MILLION.ARCA BIOPHARMA - BELIEVES CASH & CASH EQUIVALENTS AS OF MARCH 31, 2019 TO BE SUFFICIENT TO FUND OPERATIONS, AT CURRENT COST STRUCTURE, THROUGH Q1 2020.

ARCA Biopharma Says Co Entered Into Amendment No. 5 To Its Capital On Demand(Tm)Sales Agreement, Dated As Of January 11, 2017

May 20 (Reuters) - ARCA Biopharma Inc <ABIO.O>::ARCA BIOPHARMA INC - ENTERED INTO AMENDMENT NO. 5 TO ITS CAPITAL ON DEMAND(TM)SALES AGREEMENT, DATED AS OF JANUARY 11, 2017.ARCA BIOPHARMA - AMENDMENT INCREASED MAXIMUM AGGREGATE OFFERING VALUE OF SHARES OF STOCK WHICH COMAY ISSUE AND SELL BY $1 MILLION TO $16.8 MILLION.ARCA BIOPHARMA - BELIEVES ITS CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND ITS OPERATIONS THROUGH FISCAL YEAR ENDING DEC 31, 2019..

Arca Biopharma Reports Q1 Loss Per Share Of $1.86

May 8 (Reuters) - ARCA Biopharma Inc <ABIO.O>::ARCA BIOPHARMA ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $1.86.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $8.0 MILLION AS OF MARCH 31, 2019, COMPARED TO $6.6 MILLION AS OF DEC 31, 2018.ARCA BIOPHARMA-SEES CURRENT CASH, CASH EQUIVALENTS,MARKETABLE SECURITIES TO BE SUFFICIENT TO FUND OPERATIONS, AT PROJECTED COST STRUCTURE,THROUGH END OF Q3 2019.ARCA BIOPHARMA - WILL NEED TO RAISE MORE CAPITAL TO FUND FUTURE OPERATIONS,DEVELOP GENCARO/OTHER PRODUCT CANDIDATES,COMPLETE PARTNERSHIP/OTHER STRATEGIC TRANSACTIONS.

Arca Biopharma Says Filed Amendment To Implement Reverse Split Of Common Stock

April 3 (Reuters) - ARCA Biopharma Inc <ABIO.O>::ARCA BIOPHARMA INC - FILED AMENDMENT TO IMPLEMENT AN EIGHTEEN-FOR-ONE REVERSE SPLIT OF ITS COMMON STOCK AS PREVIOUSLY AUTHORIZED.ARCA BIOPHARMA INC - REVERSE SPLIT WILL BE EFFECTIVE AS OF 5:01 P.M. EASTERN TIME ON APRIL 3.

Arca Biopharma Announces Fiscal Year 2018 Financial Results

Feb 27 (Reuters) - ARCA Biopharma Inc <ABIO.O>::ARCA BIOPHARMA ANNOUNCES FISCAL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.ARCA BIOPHARMA - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $6.6 MILLION AS OF DECEMBER 31, 2018, COMPARED TO $11.8 MILLION AS OF DECEMBER 31, 2017.ARCA BIOPHARMA - BELIEVES THAT CURRENT CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL BE SUFFICIENT TO FUND ITS OPERATIONS THROUGH END OF Q3.

Arca Biopharma Has Cash And Cash Equivalents Totaling $6.6 Mln (Unaudited) As Of Dec. 31

Feb 20 (Reuters) - ARCA Biopharma Inc <ABIO.O>::ARCA BIOPHARMA INC - AS OF DECEMBER 31, 2018, HAD CASH AND CASH EQUIVALENTS TOTALING $6.6 MILLION (UNAUDITED).ARCA BIOPHARMA INC - BELIEVES THAT FUNDS WILL BE SUFFICIENT TO FUND ITS OPERATIONS, AT ITS PROJECTED COST STRUCTURE, THROUGH END OF Q2 OF 2019..

Arca Biopharma Inc - Gencaro Development Program Has FDA Fast Track Designation

Feb 20 (Reuters) - ARCA Biopharma Inc <ABIO.O>::ARCA BIOPHARMA ANNOUNCES FDA AGREEMENT FOR A SINGLE PHASE 3 CLINICAL TRIAL TO SUPPORT APPROVAL FOR THE FIRST GENETICALLY-TARGETED CARDIOVASCULAR DRUG.ARCA BIOPHARMA INC - 58% TREATMENT BENEFIT SEEN VERSUS ACTIVE COMPARATOR IN PHASE 2B FOR PLANNED PHASE 3 TARGET POPULATION.ARCA BIOPHARMA INC - GENCARO DEVELOPMENT PROGRAM HAS FDA FAST TRACK DESIGNATION.ARCA BIOPHARMA INC - U.S. AND EUROPEAN CARDIOVASCULAR PATENTS AND REGULATIONS MAY PROVIDE COMMERCIAL EXCLUSIVITY FOR GENCARO FOR 10 YEARS POST APPROVAL.

Arca Biopharma Updates Special Protocol Assessment Request To FDA

Dec 20 (Reuters) - ARCA Biopharma Inc <ABIO.O>::ARCA BIOPHARMA UPDATES SPECIAL PROTOCOL ASSESSMENT REQUEST TO FDA FOR GENCARO PHASE 3 ATRIAL FIBRILLATION CLINICAL TRIAL.ARCA BIOPHARMA INC - PHASE 3 ATRIAL FIBRILLATION TRIAL PLANNED IN POPULATION WITH NO EFFECTIVE OR FDA APPROVED THERAPIES.ARCA BIOPHARMA INC - PHASE 3 ATRIAL FIBRILLATION TRIAL PLANNED IN POPULATION WITH NO EFFECTIVE OR FDA APPROVED THERAPIES.ARCA BIOPHARMA INC - ARCA ANTICIPATES INITIATING PRECISION-AF IN SECOND HALF OF 2019.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up